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WT1, Wilms tumor 1, protein is overexpressed in a wide variety of cancers, 
including hematopoietic malignancies and solid tumors. WT1 is an attractive tumor-
associated antigen to target for cancer immunotherapy as it is not normally expressed in 
adult human tissues, except in a few restricted locations, including CD34+ cells of the 
bone marrow, glomerular podocytes of the kidney, Sertoli cells of the testis, and 
granulosa cells of the ovary. However, because of its critical role in embryonic 
development and its expression in hematopoietic stem cells (HSCs), WT1 is a self-
antigen. High affinity T cells are deleted from the repertoire in the thymus, leaving only 
low avidity T cells. Activating and expanding T cells that can recognize and kill WT1-
expressing cancers has been difficult because the frequencies of WT1-specific T cells are 
very low. Moreover, these T cells may be anergic or suppressed by regulatory T cells. To 
obtain WT1-specific T cells from mice, which also express WT1 in the spleen stroma, we 
used a spectrum of immunization strategies,  including vaccination with cDNA, protein, 
adjuvants, Listeria vaccines, WT1-expressing BMDCs, and WT1 overexpressing tumor 
cell lines. One approach to eliciting functional T cells that detect self-antigens that has 
been successful is the use of xenogeneic DNA vaccines. This approach works because the 
antigen is similar enough that cross-reactive epitopes may be utilized, but different 
enough to circumvent tolerance barriers. We created a consensus sequence DNA vaccine, 
based on homologous WT1 genes from ten different species. This maintained WT1 exons 
conserved across species, but was different enough at various amino acid positions to 
circumvent tolerance. The consensus sequence is 91% identical to the wild type murine 
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WT1 sequence. Lymphocytes from mice vaccinated with the consensus WT1 DNA 
vaccine respond to a wild type murine WT1 peptide library. Our findings suggest that 
using a consensus sequence DNA vaccine is an effective method to produce an immune 
response to a self-antigen. 
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Chapter I: Introduction 
Cancer Immunotherapy 
The American Cancer Society estimates that there will be 1.6 million new cancer 
cases this year, and the overall lifetime probability of developing cancer is over 43% in 
men, and 38% in women1,2.  Given the estimated prevalence of cancer, it is vitally 
important to develop therapies to treat cancer. While surgery, radiation and chemotherapy 
have had success in treating a variety of cancers, they also have deleterious side effects, 
may miss micro-metastases and risk relapse. The potential of cancer immunotherapy is 
that it uses the body’s own defense system to identify and precisely attack cancer cells, 
and maintain surveillance to prevent future occurances3. In the late 1800’s, William 
Coley observed a patient’s tumor disappear following an infection. He then injected other 
cancer patients with a mixture of bacteria, Coley’s toxins, which was possibly the first 
widely used cancer immunotherapy4,5. Today immunotherapies may include adjuvants, 
cytokine, antibodies, adoptive cell transfer, and vaccination which attempt to activate the 
innate and adaptive immune systems.  
The adaptive immune system is exquisitely suited to targeting a diseased cell 
while sparing normal neighboring cells, but it is the innate system that typically 
recognizes pathogens or stressed cells and starts the immune response6. The innate 
immune system is not specific for any individual pathogen and it does not lead to lasting 
immunity, but it can immediately combat a wide range of pathogens. Initially, 
antimicrobial proteins target the cell walls and membranes of bacteria, complement can 
lyse pathogens or mark them for phagocytosis by innate immune cells, and natural killer 
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cells can kill infected cells and tumor cells and produce interferon-γ (IFNγ), which 
activates many different cells of the immune system. Phagocytic white blood cells of the 
innate immune system, such as neutrophils, macrophages, and dendritic cells (DCs), can 
ingest and kill microbes and dying cells. DCs (and under certain conditions macrophages 
as well) secrete proinflammatory cytokines and present antigens derived from those 
microbes and dying cells to the cells of adaptive immune system, thereby activating 
them.  
The adaptive immune system is composed of B lymphocytes and T lymphocytes. 
Each cell has antigen receptors specific for one antigen and take a few days after 
pathogen exposure to activate, proliferate and fully develop effector functions. Briefly, B 
cells become plasma cells that secrete antibody (humoral immunity); CD8+ T cells 
become cytotoxic T cells (CTL) that directly kill cells expressing the antigen to which 
their receptors bind; CD4+ T cells may become helper T cells (TH) that support B cells 
and CD8+ T cells to become fully functional, and develop memory cells; or CD4+ T cells 
may become regulatory T cells (Treg) that suppress the activity of other lytphocytes.6 The 
innate immune system identifies features that discriminate infected, stressed cells or 
abnormal cells and microenvironments7. Features that trigger the innate immune system 
can be pathogen-associated molecular patterns (PAMPs), danger (or damage)-associated 
molecular patterns (DAMPs), inflammation or the presence or absence of certain cell 
surface markers6. PAMPs such as bacterial cell walls, and DAMPs that are released by 
tissue damage or necrotic cell death, bind and activate DCs through Toll-like receptors 
(TLRs) and other pattern recognition receptors (PRR). This causes DCs to upregulate 
antigen presentation, costimulatory markers and the secretion of cytokines8. 
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Inflammation recruits cells to the site, and enables trafficking of cells to back local lymph 
nodes, where antigen is presented to lymphocytes6. Activation of antigen presenting cells 
(APCs) by PAMPs, may be why Coley’s toxins was effective in some of his cancer 
patients. Activated DCs present antigen to T cells (signal 1) with costimulation (signal 2) 
and in the presence of proinflammatory cytokines (signal 3)7,9. The innate and the 
adaptive immune systems, bridged by DCs, work together to defend the body10. 
Therapeutic cancer vaccines attempt to take advantage of the multiple ways that 
the immune system can be educated and prodded to act by targeting both innate and 
adaptive immune cells. Ideally, the immune system has a cancer immunosurveillance 
function, in that it can specifically identify tumor cells on the basis of their expression of 
tumor-specific antigens (TSAs) and eliminate them before they can establish 
malignancy11. Some cancer cells evade immunosurveillance because they exhibit low-
level expression foreign, viral or tumor-specific antigens. They may secrete tumor-
derived factors (transforming growth factor-β (TGF-β), interleukin-10 (IL-10) to dampen 
the response in their microenvironment. Other known mechanisms of suppression include 
tumor expression of PD-L1 which binds PD-1 on T cells, thereby downregulating 
proliferation and function of effector cells12.  In the absence of TSAs, tumor-associated 
antigens (TAAs) can be used to target tumor cells. However, TAAs are self-antigens. One 
example is melanoma antigen E (MAGE). While melanoma patients may have MAGE-
specific T cells13, these lymphocytes are often ignorant of their antigen, few in number, 
and/or be tolerized or supressed14. Cancer vaccines endeavor to instruct and activate the 
immune system, by presenting a tumor specific antigen (TSA) or a tumor-associated 
antigen (TAA) in the context of danger. While some cancers, such as B cell lymphomas 
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can be eradicated by treatment with antibodies15, cellular immunity, mediated by CTL 
and TH cells, which also produce IFNγ, can directly kill cancer cells, activate other cells 
and develop memory cells to prevent relapse3. 
Wilms Tumor 1, Tumor-Associated Antigen 
Wilms Tumor 1 (WT1) is ranked at the top of the list of cancer vaccine target 
antigens in a report by the National Cancer Institutes (NIH) that prioritized antigens by:  
“(a) therapeutic function, (b) immunogenicity, (c) role of the antigen in 
oncogenicity, (d) specificity, (e) expression level and percent of antigen-
positive cells, (f) stem cell expression, (g) number of patients with 
antigen-positive cancers, (h) number of antigenic epitopes, and (i) cellular 
location of antigen expression”16.  
WT1 protein is overexpressed in at least 36 different human cancers. WT1 expression is  
correlated to progressive disease and poor prognosis17–24. For example, high levels of 
WT1 expression post-treatment of acute myeloid leukemia (AML) correlate with poor 
prognosis20, though its significance at the time of diagnosis of AML and needs to be 
clarified25,26. WT1 was originally described as a tumor suppressor gene associated with 
Wilms’ tumors, as there are mutations in ~20% of  these pediatric neoplasms27–29. 
Subsequently, it was reclassified as an oncogene because the overexpression of wild type 
WT1 is found in numerous cancers30. WT1 is overexpressed in hematopoietic 
malignancies such as AML, chronic myelogenous leukemia (CML), and myelodysplastic 
syndromes (MDS). Solid tumors such as ovarian cancer, prostate cancer, colorectal 
adenocarcinoma, breast cancer, glioblastoma and lung cancer also overexpress 
WT118,28,31. WT1 expression is necessary for the survival of breast cancer cell line MCF-
732. In glioblastomas, WT1-shRNA knockdown of WT1 significantly reduces 
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proliferation and increases apoptosis as compared to glioblastoma cells transduced with 
control shRNA33. Suppression or loss of WT1 leads to decreased tumor burden in Kras-
driven lung cancer in mouse models, and is prognostic of survival in patients with Kras-
activated lung cancers34. Knockdown of WT1, by siRNA, in lung cancer cells induces 
cell cycle arrest at the G1 phase, reduces the expression of antiapoptotic genes, and 
enhances the expression of proapoptotic genes, thereby making the cells less resistent to 
chemotherapy 30,35. 
WT1 is a zinc finger transcription factor, is involved in proliferation, cell 
differentiation and apoptosis and is critical in embryonic development. In human adult 
tissues WT1 is not expressed except for bone marrow where it has various functions in 
hematopoiesis36–38 and in the glomerular podocytes of the kidney, Sertoli cells of the 
testis, and granulosa cells of the ovary17,39. In embryonic development, it is expressed in 
tissues that arise from the mesoderm; it has an essential role in the normal development 
of the urogenital system40, the spleen41 and the epicardial epithelial to mesenchymal 
transition (EMT)42. Deletion of WT1 in the embryo results in death at mid-gestation due 
to defective coronary vasculature, even before the lack of kidney, gonad and spleen affect 
survival43,44. As WT1 is a self-antigen, developing an immune response sufficient to 
combat WT1-expressing cancers is difficult due to immune tolerance. High avidity T 
cells specific for WT1 are deleted in the thymus. The frequency of WT1-specific T cells 
in the remainder of the repertoire is reduced. The low avidity WT1 T cells that escape 
from the thymus contend with tolerance in the periphery, where they may become 
anergized or suppressed45,46.  
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Vaccination against WT1 
Current immunotherapies such as peptide or DC-based vaccines show potential in 
clinical trials. 45.8% of patients with solid tumors and  63.5% of patients with 
hematological malignancies have a clinical response (a few complete or partial 
remissions, but mainly stable disease or a reduction in WT1 transcripts); 35.4% of 
patients with solid tumors and  67.5% of patient with hematological malignancies have an 
immunological response (WT1 tetramer+, or IFNγ+  T cells)18. Most reported 
immunotherapies to treat WT1-expressing cancers are peptide-based. This restricts 
therapy to a subset of patients with compatible major histocompatibility complexes 
(MHC), and targets a few epitopes. In 2012, Doubrovina et al. reported finding 41 new 
previously unreported human epitopes for WT1 (36 presented by class I, and 5 presented 
by class II); except for WT1126-134, none of the previously described 20 epitopes, used in 
various clinical trials, produced a significant response in their study47. (WT1126-134, 
RMFPNAPYL, is considered the dominant epitope in humans and mice.) Finding the 
right epitope or peptide-MHC combination is quite a task. Vaccines which use 
autologous DC, either electroporated with WT1 mRNA or peptide pulsed, also show 
promise; however, they are by definition patient-specific, costly and require lengthy 
preparation in the laboratory18. The ideal vaccine would be safe, inexpensive, and could 
encode as much of the antigen as possible to provide multiple epitopes, for both CD8 and 
CD4 T cells, without restriction by MHC.  
In this study, we investigated immunogenicity to WT1 in wild type mice. Unlike 
humans, mice also express WT1 in the splenic stroma48. To induce a robust WT1-specific 
T cells response in mice, bordering on autoimmunity, we used a series of immunization 
7 
 
strategies including vaccinating with cDNA, protein, adjuvants, Listeria vaccines, WT1-
expressing BMDCs, and WT1 overexpressing tumor cell lines. Focusing on cellular 
immunity, mediated by CTL and TH1 T cells, we evaluated immune responses by IFNγ 
expression in ELISA (enzyme-linked immunosorbent assay), and ELISpot (enzyme-
linked immunosorbent spot) assays, and by ICS (intracellular cytokine staining). We also 
used tetramer staining to quantify WT1-specific T cells. Each vaccine strategy was 
designed to test approaches to breaking tolerance. These included supplementing the 
antigen with mechanical stress (electroporation) or molecular danger signals (PAMPs 
such as LPS, and poly(I:C)); by using Listeria monocytogenes to target antigen to APCs; 
activating APCs with cytokine, PAMPS or agonist antibody; and using cell lines that 
express WT1 nearly 100-fold greater than spleen.  
Xenogeneic DNA Vaccines 
One approach that successfully elicited an immune response to wild type antigen 
utilized a xenogeneic DNA vaccine. In mouse models of breast cancer, in which human 
Her-2 (human ErbB-2) or rat neu (rat ErbB-2) transgenic mice are electrovaccinated with 
self-antigen, the immune response is weak. Electrovaccination with heterologous 
(xenogeneic) DNA or a combination of both heterologous and self DNA, induced a more 
robust immune response, as human and rat ErbB-2 proteins are 88.1% identical49. 
Another example of  overcoming T cell tolerance, has been reported in dogs vaccinated 
with either human or murine tyrosinase to treat canine melanoma50,51. In rat experimental 
autoimmune encephalomyelitis, which is induced by guinea pig myelin basic protein, the 
shared epitope differs by one amino acid and better facilitates recognition by low-affinity 
8 
 
T cells46,52. Similar to the tolerance promoted by the expression of self-antigen Her-2/neu 
in transgenic murine brain and mammary glands, the expression of WT1 in the spleen is 
greatly tolerogenic48,53. However, unlike ErbB-2, WT1 is more highly conserved; pair 
wise alignment scores indicate a 97% identity between human and murine protein 
sequences. Since the human and the murine sequences are so similar, vaccinating mice 
with a human DNA vaccine does not work as well as it does in the Her-2/neu model. It is 
not xenogeneic enough. 
To create a more xenogeneic vaccine, we generated a consensus sequence from 
ten WT1 homologs. Homologous proteins from D. rerio, G. gallus, M. musculus, R. 
norvegicus, C. lupus, B. taurus, H. sapiens, P. troglodytes, and A. mississippiensis were 
aligned to define critically conserved domains, and to identify positions of amino acid 
variability. Amino acids, from sequences other than M. musculus, substituted at those 
sites. Additionally, the zinc finger region and nuclear localization signal was removed as 
these are typically the least immunogenic portions of a protein and sequester the protein 
in the nucleus. Kozak and IgE leader sequences were added to facilitate protein 
expression. The new protein consensus sequence is 91% identical to wild type murine 
WT1, not including the IgE leader sequence or the deleted portions. Lymphocytes from 
mice electrovaccinated with the consensus readily respond to a peptide library based on 
the wild type murine WT1 sequence, whereas the immune response to vaccination with 
the wild type murine WT1 sequence is marginal. Therefore, an increase in xenogenecity 
of the WT1 DNA vaccine leads to robust a WT1-specific cellular immune response in the 
highly tolerogenic mouse model.  
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Chapter 2: Vaccination with wild type murine WT1 does not induce a 
significant immune response in mice. 
Introduction 
A successful immune response to an antigen requires expression of the antigen in 
a fashion or environment that alerts the immune system, presentation of the antigen to 
immune cells, and in the case of cancer, an effector T cell response6. Even though 
humoral immune responses should not be discounted15, persistent memory T cells that 
remain for surveillance and prevention of relapse would be ideal. When dealing with 
foreign antigens, the cells of the immune system have a variety of pattern recognition 
receptors (PRRs) to identify characteristics of non-self in a broad assortment of 
pathogens. In addition, the adaptive immune system has an immensely diverse selection 
of lymphocyte antigen receptors, each uniquely targeted to one specific antigen. 
However, there may not be a “foreign” antigen that the immune system can distinguish, 
to indicate a rogue cancer cell. Tumor-associated antigens (TAAs), some of which can be 
viral oncogenes, or mutated or altered self-proteins, can also be overexpressed non-
mutated self-antigens, such as WT154–56. In spite of many TAAs being self-antigens, it is 
not uncommon to find T cells specific to such TAAs in patients with cancer, indicating 
that immune system can recognize these TAAs. It bolsters the hope that immunotherapy 
can be the means to treat cancer13,57.  
Immunotherapy targeting WT1, a TAA found in a wide range of cancers, requires 
designing a vaccine that can initiate a successful immune response and overcome an 
obstacle inherent in using a self-antigen as a target, namely tolerance to that antigen. 
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Central tolerance limits the number and quality of WT1-specific T cells that escape the 
thymus, as high avidity self-reactive T cells are deleted. In the periphery, these cells may 
be anergized or suppressed. In humans, WT1 expression is limited to HSC, a few cells of 
the kidney, testis and ovary. In mice, WT1 is also expressed in the stroma of the spleen, 
thereby creating an environment in which it is more difficult to make an immune 
response to WT1. Gaiger et al. and several others show that it can be done, mainly using 
peptides45,58–61. Most clinical trials, vaccinating against WT1, have used defined, and 
limited peptide vaccines, but with underwhelming results18.  
To study responses to the full length WT1 antigen, rather than a limited number 
of peptide epitopes, we vaccinated mice with full length wild type murine WT1 using a 
variety of methods, types of antigen, routes of immunization, and adjuvants in an effort to 
induce a robust immune response. Each of the methods was designed to take advantage 
of various aspects necessary for successful immune response. Route of vaccination, 
adjuvants, and vectors presented the antigen in several ways to trigger danger signals, and 
to exploit aspects of the innate and adaptive immune systems such as PRRs, transient 
inflammation, and antigen presenting cells (APCs), in order activate Wt1-specific T cells. 
We used tetramer staining and in vitro assays for IFNγ production to identify and 
quantitate cell responses in splenocytes isolated from vaccinated mice. Splenocytes or 
isolated T cells were stained with WT1 Db126 tetramer (RMFPNAPYL/H-2Db) and/or 
were restimulated in vitro by WT1 mRNA transfected B cells, using B6BL#1153 B 
lymphoma, an easily manipulated antigen presenting cell line, in IFNγ ELISA, ICS, and 
ELISpot assays.  
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Materials and Methods 
Mice 
Female or Male C57BL/6 mice between 6 to 12 weeks old were used in this 
experiment. Mice were obtained from the National Cancer Institute (Frederick, MD). 
Mouse care and experimental procedures were carried out in accordance with the 
Institutional Animal Care and Use Committee (IACUC) of Johns Hopkins University 
under an approved protocol. Female BALB/c mice between 6 to 8 weeks old were used in 
this experiment. Mice were obtained from the Jackson Laboratory. The mice were housed 
and maintained by the University Laboratory Animal Resources at the University of 
Pennsylvania in observance with the policies of the National Institutes of Health and the 
University of Pennsylvania IACUC. Naïve mice served as negative control. 
Cell lines 
B6BL#1153 is a C57BL/6 B lymphoma cell line (a kind gift of Dr. Rongfu Wang, 
Methodist Hospital Research Institute, Houston, TX). Cells were cultured in complete 
RPMI media: RPMI 1640 medium supplemented with 10% fetal bovine serum, 100 
U/mL penicillin, 100 µg/mL streptomycin, 2 mM L-glutamine, nonessential amino acids, 
10 mM HEPES buffer, and 100 µM 2-mercaptoethanol and grown at 37°C in 5% 
CO2. B1153-WT1 cell lines were generated by electroporation-mediated plasmid 
transfection of the construct pWT1, which encodes the wild type murine WT1, into 
B6BL#1153. Transfection was performed using the Nucleofector™ system (Kit V, 
Program L-013, (Lonza)) according to the manufacturer’s instructions. Transfectants 
were selected in 400 µg/ml of the neomycin analogue, G418. Drug-resistant clones were 
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selected after limiting dilution, and WT1 expression was confirmed by qRT-PCR and 
western blot. B1153-WT1 cells were maintained in complete RPMI media supplemented 
with 400 µg/ml of G418. B78H1-GM62, a C57BL/6, GM-CSF secreting cell line utilized 
in bystander immunotherapy regimens, was maintained in complete RPMI supplemented 
with high dose hygromycin (1,200 µg/mL) to assure high levels of GM-CSF expression, 
which averaged 1 µg GM-CSF/106 cells/24 h. The C57BL/6 prostate adenocarcinoma 
cell line, TRAMP-C2 (ATCC) was cultured in TRAMP media: Dulbecco's modified 
Eagle's medium with 4 mM L-glutamine adjusted to contain 1.5 g/L sodium bicarbonate 
and 4.5 g/L glucose supplemented with 5% fetal bovine serum, 5% Nu-Serum IV (BD), 
0.005 mg/ml insulin, 10 nM trans-dehydroandrosterone and 100 U/mL penicillin, 100 
µg/mL streptomycin. For TRAMP-C2/Gvax vaccination, 1x106 TRAMP-C2 cells were 
mixed with 5x104 B78H1-GM cells and irradiated (50 Gy). After three washes in PBS, 
cells were resuspended in a total of 200 µl of PBS and administered by subcutaneous 
injection (subq) of 100 µl into each hind limb. SF.TRAMP-GM (TRAMP-C2 modified to 
express GM-CSF via retroviral transduction with MFG muGM-CSF63, which averaged 
20 ng GM-CSF/106 cells/24 h) was conditioned to grow in serum free media (Dulbecco's 
modified Eagle's medium with 4 mM L-glutamine adjusted to contain 1.5 g/L sodium 
bicarbonate and 4.5 g/L glucose supplemented with 5% Ham's F12, and 0.1% MITO+ 
Serum Extender (BD), 0.005 mg/ml insulin, 10 nM trans-dehydroandrosterone, and 100 
U/mL penicillin, 100 µg/mL streptomycin). Cells used for vaccination were collected by 
trypsinization, and irradiated (50 Gy). After three washes in PBS, cells were resuspended 
in a total of 200 µl of PBS and administered by subcutaneous injection of 100 µl into 
each hind limb.   
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Relative WT1 Expression by qRT-PCR 
Quantitative PCR was performed on an Applied Biosystems 7500 real time PCR 
system. Pre-made Taqman primer/probe gene expression assays (Mouse Gapdh: 
Mm99999915_g1, Mouse Wt1: Mm01337053_m1 and Mm01337052_m1) were 
purchased from Applied Biosystems, and QuantiTect Probe RT-PCR Kit was purchased 
from Qiagen for the remainder of the reagents. Each triplicate reaction, in a total of 25 µl, 
contained 12.5 µl of the 2X master mix, 0.25 µL RT mix, 1.25 µl of the 20X Gapdh 
primer/probe, 1.25 µl of the 20X Wt1 primer/probe, DEPC treated water, and RNA 
isolated using an RNeasy kit (Qiagen). Data were analyzed using SDS 1.5 software 
(Applied Biosystems). Gapdh was used as the endogenous control and relative changes in 
gene expression were calculated using the ΔΔCt method.   
Constructs for DNA vaccination 
Wild type murine WT1 cDNA, pKS+mWT1++, was a kind gift from Dr. J. 
Kreidberg (Harvard Medical School, Boston, MA). For the generation of  pcDNA3.1 
WT1 (used for DNA vaccination and creation of a stably transfected WT1-expressing B 
cell lines), wild type murine WT1 was first amplified by PCR using pKS+mWT1++ as 
the template and a set of primers, 5’-TGTAGATCTACCATGGGTTCCGACGTGCGG-
3’and 5’-TTTGGATCCTGTCAAAGCGCCAGCTGGAGTTT-3’. The amplified product 
was then cloned into the BamHI sites of pcDNA3.1(-) vector (Invitrogen) and was named 
pWT1. An alternative WT1 construct, only used for DNA vaccination, was created by 
adding an IgE leader sequence, after which codon optimization and RNA optimization 
was performed by using GeneOptimizer® (GeneArt®, Life Technologies). The IgEL 
murine WT1 sequence was synthesized and sequence verified by GeneArt®, and cloned 
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into the expression vector pVAX (Invitrogen) and named WT1-pVAX, but will be 
referred to as pIgEL-WT1 in this manuscript. pcDNA3.1-Ova (pOva) contains ovalbumin 
fused to the transmembrane domain of transferrin. The TfR/OVA fragment was isolated 
by digestion with HindIII from the pBlueRIP-TfR/OVA plasmid, which was initially 
generated by Dr. F. Carbone (Walter & Eliza Hall Institute, Melbourne, Australia) and 
kindly provided to us by Dr. E. Sotomayer (H. Lee Moffitt Cancer Center & Research 
Institute, Tampa, FL).  
DNA vaccination by intramuscular injection only 
Each vaccinated C57BL/6 mouse received four doses of DNA plasmid on days 0, 
3, 6, and 14. Mice received 100 µg of DNA per vaccination. The DNA constructs, in 50 
µL of PBS were administered via intramuscular (IM) injection of the right or left 
quadriceps muscle. 
DNA vaccination by intramuscular injection followed by electroporation 
Each vaccinated BALB/c mouse received three doses of DNA plasmid at 14 day 
intervals. Mice received 30 µg of DNA per vaccination. Electroporation procedure was 
performed as described previously64. Briefly, DNA constructs were administered via 
intramuscular injection of the right quadriceps muscle, followed by square-wave pulses 
generated by the CELLECTRA® constant current electroporation device (Inovio 
Pharmaceuticals). The device was configured to deliver two 0.1 Amp pulses of 52 ms 
pulse width spaced apart by a 1 sec delay.  
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Constructs for in vitro transcription and transfection of B6BL#1153 B cells 
For in vitro transcription of mRNAs that are used to transfect B6BL#1153 B cells,  
all antigens are inserted into pGEM4Z/A6465. pGEM4Z/GFP/A6466 which contains GFP 
between the HindIII/EcoRI sites of pGEM4Z/A64 was kindly provided to us by Dr. I. 
Strobel (University of Erlangen, Germany). Wild type murine WT1 was amplified with a 
set of primers, 5’-TATAAAGCTTGCCACCATGGGTTCCGACGTGCGG-3’ and 5’-
TTCTGAATTCTCAAAGCGCCAGCTGGAGTT -3’, and cloned into the HindIII/EcoRI 
sites of pGEM4Z/A64, after excising GFP. Ovalbumin (Ova) was amplified with a set of 
primers, 5’-GGCCAAGCTTACCATGATGGATCAAGCTAGATCAGC-3’ and 5’-
GGGGGAATTCTTAAGGGGAAACACATCTGCCAA -3’, and cloned into the 
HindIII/EcoRI sites of pGEM4Z/A64, after excising GFP. Plasmids were linearized using 
restriction endonuclease SpeI and in vitro transcribed using the (T7) mMESSAGE 
mMACHINE high yield capped RNA transcription kit (Ambion) according to the 
manufacturer’s instructions. After digestion of the DNA template with DNase I, mRNA 
was purified with an RNeasy kit (Qiagen).  
Transfection was performed using the Nucleofector™ system (Kit V, Program L-
013, (Lonza)) according to the manufacturer’s instructions, with a few modifications. 
Briefly, each transfection consisted of 10 µg mRNA/1x107 cells in 100 µL of 
Nucleofector™ Solution V. B6BL#1153 B cells were harvested, and washed twice with 
room temperature PBS, counted, aliquoted, and pelleted. The supernatant was decanted 
and the remaining PBS aspirated. The pellet was broken with a tap of the tube, mRNA 
was added to the cells, and 100 µL of Nucleofector™ Solution V was added to resuspend 
cells and mRNA, which was then transferred to a cuvette. The cells were shocked using 
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program L-013 on a Nucleofector™ II device, rescued with pre-warmed media, and 
transferred to a 100 mm dish containing 10 ml of pre-warmed complete RPMI media. 
Cells were rested at least four hours in an incubator before use in assays. B6BL#1153 B 
cells that are simply shocked without nucleic acids were denoted as “B cells”; those that 
were transfected with wild type murine WT1 mRNA are denoted as “WT1 B cells”; those 
that were transfected with GFP or Ova mRNA are denoted as “GFP B cells” and “Ova B 
cells” respectively. 
WT1 protein expression in transfected cells  
To confirm WT1 protein expression from constructs transfected into B6-BL#1153 
B cells, 1x107 cells were lysed using 1ml of NP-40 cell lysis buffer and vortexed. Lysates 
were cleared by centrifugation. Proteins were resolved and blotted using the Bio-Rad 
Mini-Protean® TGX™ Precast Gel and Mini-Trans Blot® system. Cell lysates were 
mixed with 2X Laemmli sample buffer, supplemented with 2-mercaptoethanol and boiled 
for 5 min. Lysates were loaded onto a 10% Mini-Protean® TGX™ Gel and run at 200V 
for ~35 min. Protein was transferred onto nitrocellulose membranes in transfer buffer (IX 
Tris/Glycine/20% methanol) at 30V overnight at 4ºC. Membranes were blocked with 5% 
nonfat dry milk diluted in Tris-buffered saline + 0.1% Tween-20 (TBST), for 60 min, 
then rinsed and incubated overnight with a 1:5000 dilution of rabbit anti-WT1 
monoclonal antibody (Abcam, ab89901) TBST + 5% BSA at 4ºC. Membranes were 
washed once with TBST for 15 min, then three times with TBST for 5 min each, then 
probed with a 1:25,000 dilution of horseradish peroxidase-conjugated goat anti-rabbit 
IgG antibody (Santa Cruz Biotechnology, sc-2054) for 60 min at room temperature. 
Membranes were washed once with TBST for 15 min, then three times with TBST for 5 
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min each, then visualized using Amersham ECL Prime Western Blotting Detection 
Reagent (GE Healthcare). 
Recombinant WT1 protein and immunization with protein 
For expression of GST fusion proteins, fragments of wild type murine WT1 were 
cloned into pGEX-6P-1 (GE Healthcare). The n-terminus of WT1 (GST-N-mWT1, aa1-
193) was amplified with primers, 5’- TTTTGAATTCATGGGTTCCGACGTGCGG -3’ 
and 5’-TATTCTCGAGGTACTGCTGCTCGAACAG -3’, and cloned into the 
EcoRI/XhoI sites of pGEX-6P-1. The middle section of WT1 (GST-Mid-mWT1, aa133-
318) was amplified with a set primers, 5’-TTTTGAATTCTACCTGCCCAGCTGCCTG -
3’ and 5’-TATACTCGAGACTGGTTTCAGATGCTGACC -3’, and cloned into the 
EcoRI/XhoI sites of pGEX-6P-1. The c-terminus of WT1 (GST-C-mWT1, aa265-449) 
was amplified with a set primers, 5’-ATATGAATTCAGCAACCACGGCACAGG -3’ 
and 5’- TATTCTCGAGTCAAAGCGCCAGCTGGAG -3’, and cloned into the 
EcoRI/XhoI sites of pGEX-6P-1. To isolate GST-WT1 protein, cell lysate was prepared 
from transformed Rosetta 2(DE3)pLysS (Novagen) cell cultures.  Cells from a 1 L 
culture were harvested and centrifuged for 20 min at 4000g after a 3 h IPTG (1 mM) 
induction in Terrific broth at 30°C. Cultures producing GST-C-mWT1 were 
supplemented with 0.5 mM ZnCl2. Pellets were resuspended in a total of 25 ml of lysis 
buffer (50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 10 µM ZnCl2, 0.3% NP-40 alternative, 
0.1% Tween-20, 1 mM PMSF and Complete Mini (-EDTA) Protein Inhibitors (Roche)). 
Lysate was frozen in liquid nitrogen and thawed in a 37ºC water three times. Lysozyme 
(1 mg/ml, Sigma) was added, then the lysate was vortexed, and incubated on ice for 30 
min. The lysate was sonicated three times and then centrifuged at 12,000g at 4°C for 10 
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min. Glutathione Sepharose 4B resin (GE Healthcare), 1 ml of a 50% slurry, was washed 
with 5 ml of TBS- NMGZn wash buffer (50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 2.5 
mM MgCl2, 10 µM ZnCl2, 0.1% NP-40 alt., 10% Glycerol, and 1 mM PMSF). 
Supernatant was collected and incubated with pre-washed resin and rotated 60 min at 
4°C. The resin was centrifuged (500g) and washed three times with 5 ml of TBS-NMGZn 
wash buffer before being eluted three times with 2.5 ml of TBS-NMGZn elution buffer 
(100 mM Tris-HCl (pH 8.0), 150 mM NaCl, 2.5 mM MgCl2, 10 µM ZnCl2, 0.1% NP-40 
alt., 10% Glycerol, 20 mM Glutathione, reduced), rotated for 10 min at room 
temperature. Elutions were combined, concentrated and buffer exchanged into PBS 
before being used for immunizations. Proteins were confirmed by western blot with anti-
GST-HRP (GE Healthcare), and anti-WT1 (F-6, C-19, Santa Cruz Biotechnology) 
antibodies. Concentration was determined by Bio-Rad Protein Assay, and equal amounts 
of GST-N-mWT1, GST-Mid-mWT1, and GST-C-mWT1 were combined for GST-WT1 
protein immunizations.  C57BL/6 mice were injected intraperitoneally (IP) with 0.5 mg 
whole ovalbumin (Sigma-Aldrich) or 1 mg GST-WT1 (~0.5 mg WT1) with or without 
TLR agonists ((30 µg LPS or 50 µg poly(I:C), Sigma) and/or 50 µg of anti-CD40 mAb 
(FGK45 mAb was a kind gift of S. Schoenberger, LIAI, La Jolla, CA). Mice were 
immunized with a single injection IP and sacrificed 6 days later.  
Bone marrow-derived dendritic cells (BMDC) 
C57BL/6 mice were treated IP with 4 mg/mouse cyclophosphamide (Baxter 
Healthcare) and bone marrow was harvested 3 days after treatment. Femurs and tibiae of 
mice were removed and separated from the surrounding muscle tissue by rubbing with 
tissue. Thereafter intact bones were left in 70% ethanol for 1 min for disinfection and 
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washed with RPMI 1640. Then both ends were cut with scissors and the marrow flushed 
with RPMI 1640 using a syringe with a 25G needle. Clusters within the marrow 
suspension were disintegrated by vigorous pipetting.  The bone marrow cell suspension 
was depleted of red blood cells by lysis with ACK lysing buffer (Quality Biologicals). 
After resuspension the cells were filtered through a 40 µm nylon filter and counted. At 
day 0, bone marrow cells were plated at 0.75x106 per 100 mm dish (bacteriological) in 10 
ml serum-free BMDC media (RPMI 1640 medium supplemented with 0.1% MITO+ 
Serum Extender (BD), 100 U/mL penicillin, 100 µg/mL streptomycin, 2 mM L-
glutamine, non-essential amino acids, 10 mM HEPES buffer, and 100 µM 2-
mercaptoethanol, 1 mM sodium pyruvate, and 800 U/ml of mGM-CSF). At day 4, 
another 10 ml of media (containing mGM-CSF) were added to the plates. At day 6, half 
of the culture supernatant was collected, centrifuged; the cell pellet was resuspended in 
10 ml fresh media (containing mGM-CSF), and given back into the original plate. On day 
7, non-adherent and loosely adherent immature BMDCs were harvested, washed twice 
and the phenotype of the BMDCs (CD11c+CD11b+) were confirmed by flow cytometry 
and the cells were transfected.  
Transfection of immature BMDC was performed using the Nucleofector™ system 
(Mouse Dendritic Cell Kit, Program Y-001, (Lonza)) according to the manufacturer’s 
instructions, with a few modifications. Briefly, each transfection consisted of 10 µg 
mRNA/1x107 cells in 100 µL of Nucleofector™ Mouse DC solution. BMDCs were 
harvested, and washed twice with room temperature PBS, counted, aliquoted, and 
pelleted. The supernatant was decanted and the remaining PBS aspirated. The pellet was 
broken with a tap of the tube, mRNA was added to the cells, and 100 µL of 
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Nucleofector™ Mouse DC solution was added to resuspend cells and mRNA, which was 
then transferred to a cuvette. The cells were shocked using program Y-001 on a 
Nucleofector™ II device, rescued with pre-warmed media, and transferred to a 100 mm 
dish containing 10 ml of pre-warmed serum-free BMDC media. On day 8, the media was 
supplemented with 25 µg/ml poly(I:C) to further mature the BMDCs. On day 9, mature 
BMDCs were harvested, washed twice and the phenotype of the BMDCs (CD11c, 
CD11b, H2Kb, H2Db, IAb, CD40, CD80, CD86 (BD Biosciences)) were confirmed by 
flow cytometry. After three washes in PBS, 1x106 cells were resuspended in a total of 
200 µl of PBS and administered by subcutaneous injection of 100 µl into each hind limb.    
Listeria monocytogenes 
Stocks of vaccine-ready attenuated Listeria monocytogenes were graciously 
provided by Thomas Dubensky and Pete Lauer (Aduro BioTech). Three strains were 
provided: Lm(-), the negative control; Lm Ova, a strain that express ovalbumin protein; 
and Lm WT1-SL8, a strain that expresses full length murine WT1 protein to which 
SIINFEKL is fused at the end. C57BL/6 mice were vaccinated, intravenously with a dose 
is 5x106 CFU L. monocytogenes in 200 µL PBS.  
Splenocyte isolation 
Spleens and lymph nodes were isolated from mice, pressed through a 100 µm 
strainer to create a single-cell suspension, and red blood cells were lysed in ACK lysing 
buffer. Splenocytes were resuspended in complete media and filtered through a 40 µm 
strainer, before cell counting.  In some experiments, T cells were used enriched by using 
Pan T Cell Isolation Kits (Miltenyi Biotech) following the manufacturer's protocol. Cells 
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were cultured in complete RPMI or serum free CTL media (RPMI 1640 medium 
supplemented with 0.1% MITO+ Serum Extender (BD), 100 U/mL penicillin, 100 µg/mL 
streptomycin, 2 mM L-glutamine, non-essential amino acids, 10 mM HEPES buffer, and 
100 µM 2-mercaptoethanol, 1 mM sodium pyruvate). 
IFNγ ELISA 
Mice were sacrificed 1 week after the final vaccination, and splenocytes were 
isolated as mentioned previously. Splenocytes or T cells, from naïve and vaccinated mice 
were restimulated in vitro in 96-well flat bottom plates. Splenocytes were counted and 
added to wells at 4x105 cells per well. Peptides (2 µg/ml SIINFEKL or 5 µg/ml 
RMFPNAPYL) or 1x105 B cells (either untransfected, Ova or WT1 transfected 
B6BL#1153 B cells) were added to the wells. Wells reserved for positive and negative 
control received PMA/Ionomycin (eBioscience) or culture medium, respectively. Plates 
were subsequently placed in a 5% CO2 atmosphere incubator for 48 to 72 h, after which 
supernatant was collected, frozen, and later analyzed using mouse IFNγ ELISA (R&D 
Systems or eBioscience). Ovalbumin class I peptide SIINFEKL, and WT1 class I peptide 
RMFPNAPYL were purchased from GenScript.  
Flow cytometry and intracellular cytokine staining 
Murine CD11c, CD11b, H2Kb, H2Db, IAb, CD40, CD80, CD86, CD8, CD4, 
B220, and IFNγ antibodies were purchased from BD Biosciences and used for flow 
cytometry. PE-labeled SAINFEKL/H-2Kb tetramer (Ova), SIINFEKL/H-2Kb monomer 
(Ova) and RMFPNAPYL/H-2Db monomer (WT1) were provided by the NIH Tetramer 
Core Facility and used for identification of Ova or WT1-specific CD8+ T cells. Ova 
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monomers and WT1 monomers were tetramerized with streptavidin-PE or streptavidin-
APC (BD Biosciences) as described67. Cells were stained with tetramer for 30 min at 
room temperature, in the dark, before staining with surface antibodies. Tetramer and 
surface antibodies were diluted in lx HBSS containing 1% FBS, 10 mM HEPES buffer 
and 0.1% sodium azide. For intracellular cytokine staining, cells were fixed and 
permeabilized using the BD Cytofix/Cytoperm™ Plus Fixation/Permeabilization Kit 
(with BD GolgiPlug™ protein transport inhibitor containing brefeldin A), according to 
the manufacturer instructions. All flow data were collected using the FACSCaliber or 
LSR II (BD bioscience) and analyzed using FlowJo (TreeStar, Ashland, OR).  
Cells to be analyzed by intracellular cytokine staining for IFNγ were cultured as 
follows. Splenocytes or T cells, from naïve and vaccinated mice were restimulated in 
vitro in 48-well flat bottom plates. Splenocytes were counted and added in wells at 2x106 
cells per well. Peptides (2 µg/ml SIINFEKL or 5 µg/ml RMFPNAPYL) or 1x106 B cells 
(either untransfected, Ova or WT1 transfected B6BL#1153 B cells) were added to the 
wells. Wells reserved for positive and negative control received PMA/Ionomycin 
(eBioscience) or culture medium, respectively. Cell were stimulated in media containing 
GolgiPlug for 12 h, prior to intracellular cytokine staining.  
IFNγ ELISpot assays with individual peptides or B cells 
High-protein IP 96-well Multiscreen™ plates (Millipore, MAIPS4510) were 
coated with monoclonal mouse IFNγ Capture Antibody (R&D Systems, SEL485) and 
incubated overnight at 4°C. After three washes with 1x PBS, the plates were blocked 
with 1% BSA and 5% sucrose in 1x PBS for 2 h at ambient temperature. Mice were 
sacrificed 1 week after prime or boost vaccinations, and splenocytes were isolated as 
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mentioned previously. Splenocytes were counted and added in triplicate wells at 2.4x105 
cells per well. Peptides (2 µg/ml SIINFEKL or 5 µg/ml RMFPNAPYL) or 0.6x105 B 
cells (either untransfected, Ova or WT1 transfected B6BL#1153 B cells) were added to 
the wells. Wells reserved for positive and negative control received PMA/Ionomycin 
(eBioscience) and culture medium in lieu of peptides, respectively. Plates were 
subsequently placed in a 5% CO2 atmosphere incubator. After incubation for 18–24 h at 
37°C, the wells were washed with 1x PBS. Biotinylated anti-mouse IFNγ Detection 
Antibody (R&D Systems, SEL485) was added to each well and then incubated overnight 
at 4°C. The plates were subsequently washed and processed per a color development 
protocol provided by R&D Systems using Streptavidin-AP and BCIP/NBT Plus (R&D 
Systems, SEL002). The wells were air-dried overnight and spots inside wells were 
scanned and counted using a Zeiss KS ELISpot Imaging system. Reported spot forming 
cell counts were converted to represent spot-forming units per 1x106 splenocytes. 
IFNγ ELISpot assays with pooled peptides 
Mice in both treatment and control groups were sacrificed 1 week after the third 
immunization. Spleens were harvested from each mouse and transferred to R10 media 
(RPMI-1640 medium supplemented with 10% fetal bovine serum and 1% antibiotics). 
Using a stomacher (Seward Laboratory Systems), the spleens were pulverized and 
subsequently transferred through a 40 µm cell strainer. Erythrocytes were removed by 
adding ACK lysing buffer (Lonza). The splenocytes were isolated and resuspended in 
R10 media. High-protein IP 96-well Multiscreen™ plates (Millipore, S2EM004M99) 
were coated with monoclonal murine IFNγ Capture Antibody (R&D Systems, SEL485) 
and incubated overnight at 4°C. After three washes with 1x PBS, the plates were blocked 
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with 1% BSA and 5% sucrose in 1x PBS for 2 h at ambient temperature. Isolated 
splenocytes in R10 medium were counted and added in triplicate wells at 2x105 cells per 
well. Peptides were added to the wells. A set of peptides spanning the wild type murine 
WT1 sequence (excluding the zinc finger region) were synthesized by GenScript. The 
peptides contained 15 amino acid sequences, of which 11 residues overlapped with each 
sequential peptide. The peptides were each divided into three pools at concentrations of 2 
µg/mL/peptide.  Wells reserved for positive and negative control received Concanavalin 
A (Sigma-Aldrich, C0412) and R10 culture medium in lieu of peptides, respectively. 
Plates were subsequently placed in a 5% CO2 atmosphere incubator. After incubation for 
18–24 h at 37°C, the wells were washed with 1x PBS. Biotinylated anti-mouse IFNγ 
Detection Antibody (R&D Systems, SEL485) was added to each well and then incubated 
overnight at 4°C. The plates were subsequently washed and processed per a color 
development protocol provided by R&D Systems using Streptavidin-AP and BCIP/NBT 
Plus (R&D Systems, SEL002). The wells were air-dried overnight and spots inside wells 
were scanned and counted by an ELISpot plate reader system with ImmunoSpot®3 and 
ImmunoSpot®4 software (Cellular Technology Ltd.). Reported spot forming cell counts 




Characterization of B6BL#1153 B lymphoma (B cell) line 
In order to study the efficacy of vaccines ex vivo, we measured IFNγ production in 
splenocytes from vaccinated mice upon restimulation, using ELISA, ICS and ELISpot. 
Splenocytes were restimulated by peptide for the dominant epitope for WT1 (Db126) or 
by peptide libraries for the in vitro assays.  Responses to naturally processed and 
presented peptides were assessed using B6BL#1153, a C57BL/6 B lymphoma cell line. 
qRT-PCR ascertained that B6BL#1153 did not express WT1, while the assay reiterated 
that WT1 expression in the murine spleen was greater than that of unfractionated bone 
marrow, confirming the report of Fraizer et al36 (Figure 1A). Flow cytometric analysis 
showed that B6BL#1153 was an ideal antigen presenting cell line as it had an activated 
phenotype: high levels of MHC class I and class II, as well as costimulatory markers such 
as CD40, CD80 and CD86, without any need for supplementary activation (Figure 1B). 
Since B6BL#1153 did not naturally express WT1, the ability to easily transfect the cells 
for each experiment was important. Electroporating the cells with mRNA transfected 
greater than 90% of the viable cells in each transfection and enabled quicker protein 
expression than transfecting with plasmid DNA would have achieved. Figure 1C showed 
typical results of transfecting with GFP mRNA, in that a majority of the cells were 
transfected and highly expressed GFP protein. Electroporation of B6BL#1153 with 
pWT1 plasmid, selection in antibiotic, and dilution cloning produced WT1 stably 
transfected B cell lines that expressed WT1 comparable to that of TRAMP-C2, a murine 
prostate adenocarcinoma cell line known to overexpress WT158 (Figure 1D,E). 
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Immunization utilizing wild type WT1 cDNA produces a muted immune response as 
compared to other antigens. 
To activate the few WT1-specific T cells in the naïve repertoire, a DNA vaccine, using as 
much of the antigen as possible to provide a variety of epitopes for both CD8 and CD4 T 
cells, would be advantageous. Such a vaccine would bolster the both the cytotoxic and 
helper T cell response, but more importantly be available to a wider range of patients. 
Naked DNA vaccines are safe, easy to design and produce in volume making them an 
attractive method of immunotherapy. Plasmid DNA, intramuscularly injected, transfects 
muscle cells and tissue patrolling APCs, perturbs the tissue transiently causing 
inflammation. The plasmid itself triggers TLR9, invoking danger signals and activating 
the innate immune system, recruiting and maturing APCs68–72. T cells from mice 
vaccinated with pOva, a plasmid containing ovalbumin (Ova) sequence, responded to 
restimulation by Ova mRNA transfected B6BL#1153 cell (Ova B cells). In contrast, T 
cells from mice vaccinated with wild type murine WT1 construct, pWT1, did not produce 
IFNγ upon restimulation with WT1 mRNA transfected B6Bl#1153 cells (WT1 B cells) 
indicating that the vaccine was ineffective at activating and expanding WT1-specific T 
cells (Figure 2A).  
One limitation of DNA vaccines, is that the DNA has to be efficiently taken up by the 
muscle cells after injection and antigen presenting cells have to be recruited to the 
injection site. Electroporation can enhance the quality and magnitude of response to DNA 
vaccination.  Intramuscular DNA injection followed by electroporation, or 
electrovaccination, increases the amount of DNA entering the cells. This enhanced 
uptake is followed by increased expression, processed naturally for peptide/MHC 
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complexes, and includes an element of “danger” to stimulate the immune response73–75. 
Electroporation immediately following intramuscular injection causes more inflammation 
than a simple intramuscular injection76–80. Two WT1 DNA vaccines were compared, 
using in vivo electroporation and pooled peptide ex vivo restimulation. One group of mice 
received pWT1, while the second group received a construct in which an IgE leader 
sequence was placed in front of the murine WT1 sequence, pIgEL-WT1, to enhance 
expression of the antigen75,81. The addition of electroporation did not enhance the original 
vaccine, as splenocytes from naïve mice and mice vaccinated with pWT1 had the same 
response to murine WT1 peptides. However, splenocytes from mice vaccinated with 
pIgEL-WT1 produced a muted but slightly improved response as compared to 
splenocytes from naïve or pWT1 vaccinated mice (Figure 2B).  
Immunization with GST-WT1, anti-CD40 and adjuvant modestly enhances the 
immune response. 
Adjuvants enhance vaccines by improving the formulation or by activating the innate 
and, by extension, the adaptive immune system. TLR agonists trigger release of 
proinflammatory cytokines in monocytes, NK cells and DCs, while CD40 antibody 
activates B cells and matures DCs. Ahonen et al. and others reported that a triple 
combination of antigen, CD40 antibody, and TLR agonist, synergizes to expand antigen-
specific CTLs and differentiate them into IFNγ producing effector cells82,83. In the case of 
Ova, brief restimulation by Ova peptide (SIINFEKL) showed that mice vaccinated with 
the combination of Ova protein, CD40 antibody, and LPS (a TLR4 agonist) had the most 
IFNγ producing T cells (Figure 3A, B). This was reiterated in the 72hr IFNγ ELISA, at 
which point responses in WT1 vaccinated mice were also demonstrated. In the ELISA, T 
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cells were restimulated with either peptide or B cells transfected with Ova or WT1 
mRNA. T cells from Ova protein/αCD40/LPS vaccinated mice produced three times 
more IFNγ when stimulated with Ova B cells than with Ova peptide. Likewise, T cells 
from WT1 vaccinated mice responded better to WT1 B cells, rather than the peptide for 
the dominant epitope. However, unlike the Ova protein vaccination, the best response, 
though nearly 20-fold less, was from T cells from mice vaccinated with WT1 protein and 
poly(I:C) (a TLR3 agonist) (Figure 3D, E). The experiment was repeated with similar 
results. 
Heterologous prime/boost vaccination utilizing GM-CSF expressing cells increases 
immune responses. 
Vaccines for infectious diseases initially utilized heterologous prime/boost vaccination 
methods to present the same antigen but in different vectors to circumvent the effect of 
neutralizing antibodies to the vector backbone; however the same principle of 
heterologous prime/boost can be used for cancer vaccines. Although most cancer 
vaccines use a DNA prime followed by a viral boost vaccine, several reports demonstrate 
that a DNA prime followed by an antigen overexpressing cell line vaccine may be just as 
effective84,85. Rittich et al. showed that vaccination with E7 DNA and boosting with a cell 
line expressing E7 and GM-CSF (or IL-12), enhanced in vitro immune responses after 
vaccination, and delayed or inhibited tumor growth85. In our experiments, it was clear 
that repeated vaccinations with wild type murine WT1 DNA in a homologous prime 
boost barely produced an immune response. After boosting with TRAMP-C2/Gvax 
vaccine, in which TRAMP-C2 cells are admixed with a GM-CSF producing cell line 
before vaccination, splenocytes from heterologous DNA primed and cell line boosted 
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mice produced 250-fold more IFNγ, upon restimulation with WT1 B cells, than 
splenocytes from homologous DNA prime and boosted mice (Figure 4A); however, these 
splenocytes from TRAMP-C2/Gvax vaccinated mice also produced IFNγ when 
restimulated with B cells that were not transfected to express WT1. Since these cell lines 
were grown in serum-containing media, one possible explanation for this result was that 
fetal bovine serum (FBS) “contaminated” the vaccine86; that is along with WT1, mice 
developed an immune response to FBS. Upon restimulation, in media containing FBS, 
some splenocytes from TRAMP-C2/Gvax vaccinated mice secreted IFNγ in the absence 
of WT1 (background). To test this possibility, TRAMP-C2-GM, a cell line retrovirally 
transduced to express GM-CSF, was conditioned to grow in serum-free TRAMP media. 
However, heterologous prime boost vaccinations with a serum-free cell line showed 
elevated levels of non-WT1-specific IFNγ production (Figure 4B), suggesting that 
antigens, other than FBS, common to both TRAMP-C2 and the B6BL#1153 cells, were 
also in the immunization. 
Bone marrow-derived dendritic cells (BMDCs) grown in serum-free media do 
immunize against Ova but not WT1. 
Matured and activated dendritic cells are the ultimate antigen presenting cell6, and 
previous experiments showed that cell based vaccines enhanced immune responses, albeit 
with associated high levels of background. To avoid priming T cells to FBS, bone 
marrow cells were grown in highly supplemented, but serum-free media86–89. The 
protocol was adapted from Lutz et al90, with minor modifications from Salem et al91, and 
grown in an excess of mGM-CSF. (Please see the Material and Methods for details.) 
Phenotypic analysis and comparison of cell surface markers, on immature BMDCs grown 
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with or without FBS, revealed the serum-free BMDCs had slightly higher percentages of 
CD11b+CDl1C+ and marginally higher expression of costimulatory markers (Figure 
5A,B). Fortunately that did not hinder transfection, as greater than 50% of cells from 
each culture condition expressed GFP after electroporation with mRNA, which in itself 
has maturing effects. Incubation with TLR agonist poly(I:C) fully matured and activated 
BMDCs after 24hrs (Figure 5C, D). Before vaccination, more than 80% of the transfected 
BMDCs had very high levels of MHC II and CD80, CD86, and CD40 expression.  
To assess the ability of serum-free BMDCs to activate and expand T cells in vivo, mice 
were vaccinated with either untransfected but mature BMDC (DC), Ova-transfected and 
matured BMDC (Ova DC), or WT1-transfected and matured BMDC (WT1 DC). 
Tetramer analysis of splenocytes from naïve and vaccinated mice once again illustrated 
how difficult it was to immunize against a self-antigen, as compared to a model antigen 
such as ovalbumin (Figure 5E). Further in vitro assays bore that out, as only splenocytes 
from mice vaccinated with Ova DC, and restimulated by Ova generated increased 
amounts of IFNγ; however as noted before when using cell based vaccines, background 
IFNγ was present when splenocytes were restimulated by untransfected B cells (Figure 
5F). 
Listeria monocytogenes (Lm) vaccines do not induce immune responses to WT1 
As mammalian cell based vaccines tend to activate more T cells than those specific to the 
antigen of interest, we explored other types of vaccines. Active immunotherapies such as 
Listeria monocytogenes, a bacterial vaccine vector, are especially attractive as it is 
designed to express the antigen of interest, it activates the innate immune system, its 
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target cells are APCs and its mode of action enables cross presentation of antigens92–95. 
Listeria vaccines have been reported to break tolerance in HPV16 and Her2/neu tumor 
models96,97. We hypothesized that a WT1-expressing Listeria vaccine would elicit robust 
WT1-specific immune responses. Tetramer staining showed that vaccination by Lm Ova 
activated and expanded Ova-specific T cells, in both primary and boost responses (Figure 
6A, B respectively). The boost response to Lm Ova generated nearly a 4-fold increase in 
CD8+ Ova-specific T cells; in one mouse approximately 30% of the CD8+ T cells were 
specific for Ova. Similarly, mice vaccinated with Listeria expressing WT1-SIINFEKL 
(Lm WT1-SL8, wherein the fusion protein is WT1 with an Ova class I peptide tag) also 
had Ova specific T cells that expanded with boost vaccination to over 10% of the CD8+ T 
cells. ELISpot assays that restimulated the splenocytes with peptide or Ova B cells 
reiterated the tetramer analysis (Figure 6C, D). In contrast, no WT1-specific response 
was observed in the primary or boost responses. Mice that were subsequently challenged 
with 1x106 or 3x106 TRAMP-C2 cells did develop WT1-specifc T cells; however, prior 
immunization with LmWT1-SL8 had no significant effect on this response. The 
frequency of WT1-specific T cells in both naïve mice as well as Listeria vaccinated mice 
was the same (Figure 7). To test the hypothesis that a heterologous prime-boost regimen 
would be capable of breaking WT1 tolerance, mice were vaccinated with WT1-
expressing BMDCs, then boosted with LmWT1-SL898. Tetramer analysis identified an 
Ova-specific T cell response but not a WT1-specific T cell response (Figure 8A). Upon 
challenge with 0.25x106 TRAMP-C2 cells, there was a slight increase in WT1-specific T 




It is evident that attempting to produce an immune response to full length wild 
type WT1 is very difficult. Each of the vaccine strategies tested elicited responses to 
ovalbumin, which is a foreign antigen, while none utilizing murine WT1, a self-antigen, 
produced a robust response. Vaccine strategies included cDNA vaccination, protein plus 
adjuvant, BMDCs, Listeria and WT1 overexpressing whole cell vaccination.  
The first strategy, DNA vaccination, one the major immunotherapeutic tools, 
could not activate an immune response with wild type WT1 cDNA in spite of  
supplementing the vaccination with electroporation which should have increased cellular 
uptake of plasmid and produced localized transient inflammation. However, there are 
many improvements that can be made. Newer electroporation devices can electroporate 
not only muscle, but also subcutaneous and epidermal layers of the skin so that 
Langerhans DCs can be targeted. The plasmid DNA can be altered to include genetic 
adjuvants. In the next chapter, we test the hypothesis that altering the sequence of WT1 
cDNA will increase immunogenicity.   
A second vaccination strategy involved wild type murine WT1 protein, CD40 
antibody and adjuvant. WT1 protein and poly(I:C) created a minor immune response, 
which was reproducible, but surprising as it was expected that the best vaccine 
formulation would have included CD40 antibody as was seen when Ova was the antigen. 
What was not surprising was that poly(I:C), a TLR3 agonist that mimics dsRNA, typical 
of viruses and intracellular pathogens, was the better adjuvant for a WT1 vaccine as WT1 
is a self-antigen that normally shuttles between cytoplasm and nucleus and is not 
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secreted. As Ova is typically secreted, LPS, a TLR4 agonist found in bacteria and 
extracellular pathogens, delivered better results for the Ova vaccine.  
The third vaccination strategy used whole cell vaccines, such as TRAMP-
C2/Gvax. It provided the greatest immune response to WT1. The GM-CSF matured and 
activated monocytes and DCs. It also prepared them to produce proinflammatory 
cytokines, which would attract more immune cells to the site of vaccination. Given that 
WT1 expression in TRAMP-C2 is nearly two logs greater than WT1 expression in the 
spleen, it may be a simple matter of quantity of antigen presented; however, unless 
treated with IFNγ, which was not done here, TRAMP-C2 does not express great 
quantities of either MHC class I or class II. It may be pertinent to ascertain that, while 
likely, the WT1 overexpressed in this cell line is the wild type version.  
The fourth vaccination strategy, immunization with mature WT1-expressing 
BMDC failed to elicit a response to WT1. As mature, activated professional antigen 
presenting cells, expressing high levels of MHC I and II, as well as costimulatory 
markers, and efficiently transfected with antigen, serum-free BMDCs activated naïve 
Ova-specific T cells, but not WT1-specific T cells. Even though the BMDCs were 
cultured, transfected, and matured with poly(I:C), in the exact same fashion, the tolerance 
to WT1 hindered any responses. Dannull et al. demonstrated that selective (and transient) 
in vivo depletion of regulatory T cells (Treg), which suppress immune responses, help to 
break tolerance when used in conjunction with DC vaccines99. Reports also indicate that 
providing a third signal, proinflammatory cytokines such as IL-12, is necessary to break 
tolerance and prevent deletion or anergy9. It would be wise to check cytokine production 
of the serum-free BMDCs before utilizing them for any future vaccines. Such 
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modifications to the vaccination may help abrogate the profound tolerance to WT1. 
Additionally, whole cell vaccines, such as TRAMP-C2 or BMDCs, primed responses to 
antigens other than WT1. In clinical trials, that may be advantageous, if a patient’s tumor 
is part of a GVAX® vaccine, but non-tumor-specific immune responses can also arise100. 
Non-Ova or non-WT1-specific IFNγ production detracted from the significance of the 
response in ELISpot, ELISA or other IFNγ in vitro assays.  
The fifth strategy, Listeria monocytogenes vaccines did not elicit background 
IFNγ production, but splenocytes from LmWT1-SL8 vaccinated mice also had no 
detectable WT1 response, using either by tetramer staining or ELISpot assays. The same 
vaccine was able to prime and boost a response to the Ova tag at the end of the WT1 
fusion protein. Goldberg et al have reported that profound tolerance to self-antigen can be 
mitigated if the PD-1/PD-L1 interaction is blocked by antibodies during immunization 
with self-antigen expressing Listeria monocytogenes101.  
Overall, these data show that future experiments should address not only 
presentation of antigen but mechanisms of peripheral tolerance, such PD-1/PD-L1, 






Figure 1. Characterization of B6BL#1153 B lymphoma (B cell) line. 
(A) Relative expression of WT1 in C57BL/6 mouse bone marrow, spleen and B6 BL#1153 B cell 
line using mRNA isolated from tissues and cell line in a qRT-PCR assay. Bone marrow is normalized 
to 1. Each column represents the average of triplicates. Error bars show standard deviation of the 
mean. (B) B6BL#1153 B cell expression of MHC I, II, and costimulatory markers. (C) GFP 
expression 24 h after transfection (electroporation) of B6BL#1153 B cells with GFP mRNA. Data are 







Figure 1.  (continued)  
(D) Relative expression of WT1 in murine bone marrow (BM) and spleen, B cells (untransfected 
B6BL#1153 B cells), GFP B cells (B6BL#1153 B cells transfected with GFP mRNA) and B1153-
WT1 #6, #11 (two WT1 stably transfected B6BL#1153 B cell lines), and TRAMP-C2, a WT1-
overexpressing prostate cancer cell line, using mRNA isolated from tissues and cell lines in a qRT-
PCR assay. Spleen was normalized to 1. Each column represents the average of triplicates (+/-SD). 
Data are representative of at least three assays. (E) Western blot of mock transfected  B6BL#1153 B 
cells (where cells are shocked without mRNA), B cells (untransfected B6BL#1153 B cells), WT1 B 
cells (B6BL#1153 B cells transfected WT1 mRNA) and B1153-WT1 (WT1 stably transfected  




Figure 2.  Immunization utilizing wild type WT1 cDNA produces a muted immune response as 
compared to other antigens. 
(A) C57BL/6 mice were immunized by IM injection with 100 µg pOva or pWT1 plasmid per mouse on 
Days 0, 3, 6, 14, and seven days (Day 21) after the last vaccination mice were sacrificed, and T cells 
were restimulated by B cells (untransfected B6BL#1153 B cells), or Ova mRNA or WT1 mRNA 
transfected B6BL#1153 B cells, (Ova B cells or WT1 B cells)  for 48 h, after which supernatant was 
collected and used in a mouse IFNγ ELISA. Data are representative of two independent experiments. 
Average (+/-SD) of three mice per group. (B) Two WT1 DNA vaccines are compared: 1) a construct in 
which an IgE leader is added to the murine WT1 sequence, pIgEL-WT1 and 2) an unaltered murine 
WT1 sequence, pWT1. One week after the fourth biweekly vaccination (30 µg of DNA by intramuscular 
injection followed by electroporation at injection site), mice were sacrificed, and splenocytes from 
BALB/c mice are restimulated with pools from a murine WT1 peptide library for 24 hours in 96 well 
ELISpot plates coated with antibody to IFNγ. Individual mice are shown for each group. Each column 





Figure 3.  Immunization with GST-WT1, anti-CD40 and adjuvant modestly enhances the immune 
response. 
C57BL/6 mice were immunized IP with 500 µg of whole ovalbumin or WT1 protein, with or without 50 
µg of the anti-CD40 antibody (FGK45), and/or 30 µg of LPS, and/or 50 µg of poly(I:C) in the 
combinations indicated above. Mice were sacrificed 6 days after immunization, spleens were harvested 
and T cells isolated. T cells were restimulated with either peptide, untransfected B cells, or Ova or WT1 
mRNA transfected B cells.  (A-C) Frequency of CD8+ IFNγ+ T cells from representative mice, after 













Figure 3.  (continued) 
(D, E) After 72 h of restimulation with peptide or B cells, supernatant was collected and assayed 
using mouse IFNγ ELISA. Each column represents the average of triplicates (+/-SD). Data are 







Figure 4.  Heterologous prime/boost vaccination utilizing GM-CSF expressing cells increases 
immune responses. 
C57BL/6 were immunized by IM injection with 100 µg pWT1 plasmid per mouse on Days 0, 3, 6, 14,  
and on Day 21 mice were immunized, subq, with either (A) TRAMP-C2/Gvax or (B) serum-free 
TRAMP-C2-GM. Seven days after the last vaccination mice were sacrificed, and T cells were 
restimulated by untransfected B6BL#1153 B cell (B cell) or transfected with WT1 mRNA (WT1 B 
cells) for 48 h, after which supernatant was collected and used in a mouse IFNγ ELISA. Data are 




    
Figure 5.  Bone marrow-derived dendritic cells (BMDCs) grown in serum-free media do immunize 
against Ova but not WT1. 
Cell surface markers of immature BMDCs grown in (A) serum-free media or in (B) FBS-containing 
media before transfection with mRNA. Comparison of transfection efficiency and maturation using GFP 
mRNA to transfect immature BMDCs and poly(I:C) to mature BMDCs cultured without (C) or with FBS 
(D). Mice were immunized, subq, with serum-free, matured BMDCs, that were either untransfected (DC), 
or Ova or WT1 mRNA transfected (Ova DC and WT1 DC respectively). Mice were boosted 7 days later 
with the same type of BMDC, then sacrificed 7 days after the boost vaccination and spleen cells were 
isolated. (E) Tetramer analysis 7 days after boost vaccination.  Splenocytes were stained with PE-labeled 
SAINFEKL/H-2Kb tetramer (OVA Tetramer) and APC-labeled RMFPNAPYL /H-2Db tetramer (WT1 
Tetramer) and were gated on B220- CD8+ cells. (F) Frequency of CD8+ IFNγ+ T cells, after restimulation 
by peptide or B cells. Splenocytes were restimulated with either peptide, untransfected B6BL#1153 B 
cells (B cell), or Ova or WT1 mRNA transfected B6BL#1153 B cells (Ova B cell and WT1 B cell 
respectively), for 12 h in serum-free media and followed by intracellular staining for IFNγ. (G) 
Splenocytes were restimulated by indicated B cells for 24 hours in serum-free media in 96 well ELISpot 
plates coated with antibody to IFNγ. Data are representative of four independent experiments. Average 












Figure 6.  Comparison of immune response to foreign and self-antigens using L. monocytogenes 
vaccines. 
Mice were primed with control Listeria (Lm (-)), ova-expressing Listeria (Lm Ova), WT1-SIINFEKL-
expressing Listeria (Lm WT1-SL8) or unvaccinated (Naïve). Day 7 after priming, 3 mice from each 
group were sacrificed and splenocytes were assayed by tetramer and IFNγ ELISpot. The remainder of the 
mice were boosted 21 days after priming with the same Listeria vaccine with which they were primed. 6 
days after boosting another 3 mice from each group were sacrificed and splenocytes were assayed. (A) 
Tetramer analysis of the primary response (day 7). Splenocytes were stained with PE-labeled 
SIINFEKL/H-2Kb tetramer (OVA Tetramer) and APC-labeled RMFPNAPYL/H-2Db tetramer (WT1 
Tetramer) and were gated on B220-
 
CD8+ cells. (B) Tetramer analysis of the boost response 6 days after 
boosting. (C) IFNγ ELISpot assay of the primary response (day 7). Splenocytes were restimulated with 
media, peptide (either Ova peptide (SIINKEKL) or WT1 peptide (RMFPNAPYL)), or with B6BL#1153 
B cells (either untransfected (B cell), or transfected with either Ova mRNA (Ova B cell) or WT1 mRNA 
(WT1 B cell)). (D) IFNγ ELISpot assay of the boost response, 6 days after boosting. Data are from a pilot 











Figure 7.  TRAMP-C2 tumor challenge, after L. monocytogenes vaccination, induced WT1-specific 
T cells.  
Naïve mice or mice primed and boosted with LmWT1-SL8 vaccine were inoculated 7 days after the 
boost vaccination with either 1x106 or 3x106 TRAMP-C2 tumor cells, subq. Tetramer analysis of 
splenocytes from mice sacrificed after completion of the tumor challenge, 36 days after tumor 
inoculation. Splenocytes were stained with PE-labeled SIINFEKL/H-2Kb tetramer (OVA Tetramer) and 
APC-labeled RMFPNAPYL/H-2Db tetramer (WT1 Tetramer) and were gated on B220- CD8+ cells. Data 





Figure 8.  Heterologous Prime/Boost did not induce WT1-specific T cells while TRAMP-C2 
tumor challenge activated WT1 primed T cells.  
Mice were primed with 2.5x105 matured and activated BMDC that were either untransfected (DC (-)) 
or transfected with WT1 mRNA (DC WT1) or remained unvaccinated (Naïve). Mice were boosted 6 
days after priming with Lm(-), LmWT1-SL8 or remained unvaccinated. 5 days after boosting, 3 mice 
from each group were sacrificed and splenocytes were assayed with by tetramer.  24 days after the 
boost vaccination, the remainder of the mice (n=5 per group) were challenged with 0.25x106
  
TRAMP-C2 tumor cells, subq. Tetramer analysis of the (A) boost response and (B) tumor challenge 
response. Splenocytes were stained with PE-labeled SIINFEKL/H-2Kb tetramer (OVA Tetramer) and 
APC-labeled RMFPNAPYL/H-2Db tetramer (WT1 Tetramer) and were gated on B220- CD8+ cells. 




Chapter 3: Vaccination with consensus WT1 cDNA intramuscular 
injection followed by electroporation induces an immune response to 
wild type WT1. 
Introduction 
As seen from the experiments detailed in chapter 2, mice are profoundly tolerant 
to wild type murine WT1. Matured and activated BMDC expressing wild type WT1 
failed to induce WT1-specific T cells. Since even a fully functional professional antigen 
presenting cell was unable to elicit an immune response to the wild type antigen, we next 
hypothesized that altering the antigen would elicit an immune response that could  
recognize wild type WT1.  Adding an IgE leader sequence to WT1 in a DNA vaccine 
construct, to facilitate expression, minutely improved the response (Figure 2B); more 
radical changes were necessary. Xenogeneic DNA vaccines are one approach to eliciting 
functional CTL that recognize self-antigens. Xenogeneic DNA are immunogenic because 
the antigen is similar enough that cross-reactive epitopes are utilized but different enough 
to circumvent barriers, such central and peripheral tolerance. Ideally, heteroclitic epitopes 
may be better able to bind peptide-MHC or the T cell receptor (TCR) and activate low 
avidity T cells. Subtle amino acids changes may affect the way the antigen is processed, 
possibly causing increased protein degradation, and presentation. Because the murine and 
human WT1 proteins are 97% identical, using human WT1 to vaccinate mice would be 
ineffective. To solve this problem, in collaboration with David Weiner and Jewell 
Walters (University of Pennsylvania, Philadelphia, PA) a consensus sequence DNA 
vaccine was created. The consensus is based on the alignment of homologous WT1 genes 
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from ten different species. The consensus WT1 sequence maintained conserved WT1 
domains but was different enough at various amino acid positions to circumvent 
tolerance, as the consensus sequence is 91% identical to the wild type murine WT1 
sequence. Lymphocytes from mice vaccinated with the consensus WT1 DNA vaccine 
responded to a peptide library based on the wild type murine WT1 sequence. Our 
findings suggest that using a consensus sequence DNA vaccine may be an effective 




Materials and Methods 
Construction of WT1 consensus sequence.  
D. rerio, G. gallus, M. musculus, R. norvegicus, C. lupus, B. taurus, H. sapiens, 
P. troglodytes, and A. mississippiensis gene sequences were collected from GeneBank, 
and the consensus WT1 nucleotide sequence was obtained after performing multiple 
alignment. After obtaining the WT1 consensus sequence, an IgE leader sequence was 
added, and codon optimization and RNA optimization was performed by using 
GeneOptimizer® (GeneArt®, Life Technologies).  
WT1 DNA immunogen.  
The WT1 consensus sequence was synthesized and sequence verified by 
GENEART, and cloned into the expression vector pVAX (Invitrogen) and was named as 
WT1-pVAX-S but will be referred to as pConWT1 in this manuscript. Alternate 
constructs of the WT1 DNA vaccine have been previously mentioned. Briefly, wild type 
murine WT1 was cloned into pcDNA3.1, named pWT1, and a codon optimized murine 
WT1 (with an IgE leader sequence) was cloned into pVAX and named WT1-pVAX , but 
will be referred to as pIgEL-WT1 in this manuscript. 
Mice 
Female C57BL/6 mice between 6 to 8 weeks old were used in these experiments. 
Mice were obtained from the Jackson Laboratory. The mice were housed and maintained 
by the University Laboratory Animal Resources at the University of Pennsylvania in 
observance with the policies of the National Institutes of Health and the University of 
Pennsylvania Institutional Animal Care and Use Committee (IACUC). The mice used in 
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these experiments were separated into groups of five for immunization. Mice were 
immunized with pConWT1, pIgEL-WT1 or pWT1. Naïve mice served as negative 
control. 
DNA vaccination and electroporation 
Each mouse received four doses of DNA plasmid at 14-d intervals. Mice received 
25μg to 75μg of DNA per vaccination. The DNA constructs were administered via 
intramuscular injection of the right quadriceps muscle, followed by square-wave pulses 
generated by the CELLECTRA® constant current electroporation device (Inovio 
Pharmaceuticals). The device was configured to deliver two 0.1 Amp pulses of 52 ms 
pulse width spaced apart by a 1 sec delay. Electroporation procedure was performed as 
described previously64. 
IFNγ ELISpot assays  
Mice in both treatment and control groups were sacrificed 1 week after the third 
immunization. Spleens were harvested from each mouse and transferred to R10 media 
(RPMI-1640 medium supplemented with 10% fetal bovine serum and 1% antibiotics). 
Using a stomacher (Seward Laboratory Systems), the spleens were pulverized and 
subsequently transferred through a 40 µm cell strainer. Erythrocytes were removed by 
adding ACK lysing buffer (Lonza). The splenocytes were isolated and resuspended in 
R10 media. High-protein IP 96-well Multiscreen™ plates (Millipore, S2EM004M99) 
were coated with monoclonal murine IFNγ Capture Antibody (R&D Systems, SEL485) 
and incubated overnight at 4°C. After three washes with 1x PBS, the plates were blocked 
with 1% BSA and 5% sucrose in 1x PBS for 2 h at ambient temperature. Isolated 
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splenocytes in R10 medium were counted and added in triplicate wells at 2x105 cells per 
well. Peptides or 0.5x105 B cells (either untransfected, or WT1 mRNA transfected 
B6BL#1153 B cells, or B1153-WT1 stably transfected cell line) were added to the wells. 
Two sets of peptides spanning the consensus WT1 sequence and the wild type murine 
WT1 sequence (excluding the zinc finger region) were synthesized by GenScript. The 
peptides contained 15 amino acid sequences, of which 11 residues overlapped with each 
sequential peptide. The peptides for each WT1 set were each divided into three pools at 
concentrations of 2 µg/mL/peptide. Wells reserved for positive and negative control 
received Concanavalin A (Sigma-Aldrich, C0412) and R10 culture medium in lieu of 
peptides, respectively. Plates were subsequently placed in a 5% CO2 atmosphere 
incubator. After incubation for 18–24 h at 37°C, the wells were washed with 1x PBS. 
Biotinylated anti-mouse IFNγ Detection Antibody (R&D Systems, SEL485) was added 
to each well and then incubated overnight at 4°C. The plates were subsequently washed 
and processed per a color development protocol provided by R&D Systems using 
Streptavidin-AP and BCIP/NBT Plus (R&D Systems, SEL002). The wells were air-dried 
overnight and spots inside wells were scanned and counted by an ELISpot plate reader 
system with ImmunoSpot®3 and ImmunoSpot®4 software (Cellular Technology Ltd.). 
Reported spot forming cell counts were converted to represent spot-forming units per 
1x106 splenocytes. 
Epitope mapping 
Epitope mapping studies were performed to determine the dominant epitopes 
within both consensus and mouse-matched WT1 peptide libraries. Combinatorial peptide 
libraries specific for wild type WT1 were established by setting up 18 peptide pools, each 
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pool consisting of eight to nine peptides combined in such a way that each individual 
library peptide was shared once by two particular pools. Combinatorial peptide libraries 
specific for consensus WT1 were established by setting up 17 peptide pools, each pool 
consisting of eight to nine peptides combined in such a way that each individual library 






Consensus Sequence Construct.  
Initial experiments using wild type murine WT1 cDNA (either in its original 
pcDNA3.1 vector, or in a pVAX vector fused after an IgE leader sequence) to vaccinate 
mice elicited minimal immune responses, even when electroporation was included in the 
vaccination protocol. Therefore, a WT1 consensus sequence DNA vaccine was created 
by aligning homologues of WT1 from various species including human, mouse, rat, dog, 
and chimpanzee. The sequences were aligned to define the critically conserved domains, 
and identify positions of amino acid variability. For example, in M. musculus WT1 
protein there is a 17 aa domain (exon 5) that is not conserved across the species and the 
exon is a commonly seen splice variant; therefore, this 17 aa domain was not included in 
the consensus sequence. Doubrovina et al. also reported finding epitopes across the 
breadth of human WT1 excepted for this 17 aa domain, even though their peptides were 
based on the full length sequence47. Another example, at amino acid position 136 where 
there is a serine in the M. musculus sequence that has been changed to the asparagine 
seen in the D. rerio sequence.  The sequence was further modified by tRNA codon and 
RNA optimization, and a Kozak sequence and a highly efficient leader sequence was 
fused in frame upstream of the start codon to facilitate expression. Not included in the 
construct was a proline rich region, the variably spliced exon 5, and the zinc finger 
domain, which contains the nuclear localization signals102 (Figure 9A). Removal of the 
zinc finger region that would normally sequester the protein in the nucleus, allows for 
more secretion of the protein from the muscle cells that have been transfected. This 
protein can be taken up by DCs resident in the tissue. Alignment of the final consensus 
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WT1 sequence shows a 91% similarity to the original wild type murine WT1 sequence 
and illustrates the amino acid differences between the two (Figure 9B). The dominant 
epitope reported in the literature WT1126-134 (RMFPNAPYL) is unchanged. The final 
construct was cloned into pVAX vector, and is here referred to as pConWT1. Highly 
purified and concentrated DNA was used to vaccinate mice by intramuscular injection, 
immediately followed by electroporation. 
Consensus WT1 DNA vaccine induces a stronger immune response than wild type 
murine WT1 DNA vaccine.  
 To compare the immunogenicity of the consensus WT1 construct to previous 
wild type WT1 constructs, mice received 25 µg of either pConWT1, pIgEL-WT1 or 
pWT1 vaccines (Figure 10). Upon restimulation, in vitro with pooled peptide from the 
consensus library sequence in an IFNγ ELISpot, splenocytes, from mice vaccinated with 
pConWT1 demonstrated clear unequivocal immune responses. Splenocytes from pIgEL-
WT1 vaccinated or pWT1-vaccinated mice did not respond to consensus peptides. 
Although it is possible that these WT1-specific splenocytes could not recognize 
consensus peptide, but it is far more likely that those splenocytes lack WT1-specific T 
cells as seen previously in chapter two. To elicit a significant immune response to a self-
antigen, actually changing portions of the antigen was necessary, whether it be truncation 
or individual amino acid substitutions.   
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Increasing the amount of consensus WT1 DNA increases the immune response to 
wild type WT1 peptides. 
To further validate the use of pConWT1, splenocytes, from mice immunized with 
increasing doses of pConWT1, proved that they had increasing numbers of WT1-specific 
cells. Pools of wild type mouse-matched WT1 peptides restimulated these splenocytes, 
indicating that consensus WT1 vaccination activated and expanded WT1-specific T cells 
that recognized murine WT1.  The dose-response curve shows increasing the amount of 
the consensus WT1 DNA electroporated into the muscle of the mouse does increase the 
number of IFNγ positive cells upon restimulation in vitro with a wild type murine WT1 
peptide library (Figure 11). The immunogen is essentially xenogeneic but the response 
contains activated or memory T cells that can identify and respond to the murine WT1 
antigen. 
Splenocytes from pConWT1-vaccinated mice do not respond to endogenously 
expressed WT1. 
Since splenocytes from pConWT1-vaccinated mice responded to wild type 
murine WT1 peptides, we restimulated these splenocytes with B cells expressing wild 
type murine WT1, either a stably transfected cell line or one that was transfected with 
mRNA the evening before mice were sacrificed. In either case, very few splenocytes 
from pConWT1-vaccinated mice produced any IFNγ, at least not above the level of 
background (Figure 12). This is not an unprecedented result as Ramirez et al. also 
observed a similar phenomenon, where peptide loaded BMDC vaccination induced WT1-
specific CTLs, that could be restimulated in vitro by peptide, but could not recognize 
antigen on WT1-expressing cells103.  
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Epitope mapping using the wild type mouse-matched WT1 peptide library identifies 
epitopes other than WT1 Db126 
In order to define the epitopes within WT1 to which these T cells are responding, 
epitope mapping was done with combinatorial pools of peptide from either the consensus 
WT1 library (Figure 13) or the wild type murine WT1 library (Figure 14). The libraries 
were composed of 15mer peptides, overlapping by 11 amino acids.  A matrix system was 
used in which peptides were pooled by row or columns, allowing each peptide to be 
represented twice, and tested in duplicate. Screening with the consensus WT1 library 
isolated peptide #28 ARMFPNAPYLPNCLE, which contains the well-characterized 
epitope RMFPNAPYL (aa 126-134). This is the dominant epitope for C57BL/6 and 
BALB/c mice and HLA-A0201 humans. Alignment of consensus peptide #28 that was 
identified in the consensus WT1 library, to consensus and wild type sequences revealed 
that the only difference between this 15mer peptide and the wild type murine WT1 
sequence is the second asparagine is a serine in the wild type sequence (aa 136), outside 
of the known epitope (Figure 15A).  Screening with the wild type murine library showed 
immune responses, above background, in three pools, #1, 9 and 12 which identified 
peptides #19 (EEQCLSAFTLHFSGQ) and 27 (PSQASSGQARMFPNA), which were 
then aligned to both sequences and compared (Figure 15B). Each of the wild type 
peptides differ from the consensus sequence at one amino acid. Wild type peptide #19 
may contain a novel murine WT1 epitope as it has not been mentioned in the literature 
while peptide #27 contains QASSGQARM which was studied by Naylor et al104 and Dai 
et al105 with conflicting results. These epitope mapping assays need to be repeated to 
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confirm the results, but with splenocytes from mice vaccinated with 50 µg of pConWT1 





Given the overexpression of WT1 in a multitude of cancers, an effective 
immunotherapy targeting this tumor-associated antigen would be beneficial; 
however, because WT1 is a self-antigen, generating a substantial WT1-specific 
immune response is difficult due to tolerance barriers such as deletion of high avidity 
T cells in the thymus, and possibly anergy and suppression in the periphery as well. 
In a highly tolerogenic mouse model, in which WT1 is expressed not only in a few 
restricted cells of certain tissues, but in the stroma of the adult murine spleen as well, 
our consensus WT1 DNA vaccine may circumvent tolerance and generate a 
significant T cell immune response. 
In the thymus, central tolerance is established whereby self-reactive T cells 
that have TCRs with a high affinity for self-peptide-MHC are deleted, anergized or 
differentiated into regulatory T cells to prevent autoimmunity106. The T cells that do 
escape the thymus have TCRs that recognize foreign antigens or have a low affinity 
for self-peptide-MHC. While this is normal, it poses a problem for cancer 
immunotherapies which target tumor-associated antigens, some of which are 
aberrantly expressed or overexpressed self-antigens. In a report by Aleksic et al., ten 
viral antigen (VA)-specific TCRs and 14 tumor-associated peptide antigen (TAPA)-
specific TCRs (including 3 WT1-specific TCRs) were compared based on their 
affinity to their corresponding peptide-human leukocyte antigen complex (in this 
case pHLA-A0201). It was clear that VA-specific TCR-pHLA interactions tended to 
have lower dissociation constants (KD) and on average longer half-lives (t1/2) than 
their TAPA-specific counterparts107. For example, a HIV-specific TCR had a KD of 
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0.18 µM and a t1/2 of 27 seconds, while one of the WT1-specific TCRs had a KD of 
45µM and a t1/2 of <0.5 seconds107. The HIV-specific TCR has a higher affinity for 
its pHLA as it binds it more tightly, requires less to reach equilibrium, and remains 
bound longer, than theWT1-specific TCR.  The lower affinity WT1-specific TCR 
requires 250x more pHLA to reach equilibrium and even then the interaction may 
last less than half a second. Pinilla-Ibarz et al. reported that they were able to design 
analog heteroclitic WT1 peptides with a longer half-life and were able to elicit CTL 
responses; however, these peptides were designed to bind better specifically to HLA-
A0201108.  A higher affinity, and a longer TCR-pMHC interaction produced a 
stronger immune response, but it was relevant only to those who have the matching 
HLA. 
In an effort to create an ideal WT1-specific TCR, Schmitt et al. designed two 
enhanced-affinity complementarity determining region (CDR) 3α mutants. Both  
mutants had higher affinity for WT1-Db (RMFPNAPYL) than the wild type TCR, but 
one had higher functional avidity, in vitro, as well109. TCR transduced T cells were 
injected into mice that were subsequently immunized with WT1 peptide-pulsed 
splenocytes, then boosted with Listeria monocytogenes expressing the WT1 
RMFPNAPYL epitope. They showed that the T cells expressing the enhanced-affinity 
TCRs expanded in vivo 1.5 to 1.6x greater than the T cells expressing the wild type WT1 
TCR, without causing autoimmunity109. While this method of enhancing the WT1-
specific immune response is encouraging as it doesn’t depend on the immunocompetence 
of the subject and “replaces” the high avidity WT1-specific T cells that are deleted due to 
central tolerance, it focuses on one epitope, requires mutation of the TCR and 
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transfection of syngeneic T cells. If it were translated to the clinic, it would need to be 
tailored for each patient, or else may limit the type of patient for which it would be 
effective, due to histocompatibility issues.  
If one cannot “replace” high avidity WT1-specific T cells, another approach to the 
problem would take into account that the low avidity T cells require more antigen to 
engage their TCRs sufficiently, and immunize subjects with more antigen. For example, 
C57/BL6 mice can be immunized with TRAMP-C2, a prostate adenocarcinoma that 
overexpresses WT1 several logs higher than what is seen in the murine spleen, and 
produce a significant immune response; however, the response is not only to WT1, but 
also to a plethora of other antigens expressed by the cell line and found in the culture 
media. While immunizing with a WT1 overexpressing cell line addresses the issue of 
quantity of antigen, it doesn’t address the typically shorter half-life of the TCR-pMHC 
interaction of low avidity T cells. 
To address both concerns, quantity of antigen and possibly quality of TCR-pMHC 
interaction, we created a consensus based WT1 DNA vaccine that is injected 
intramuscularly, immediately followed by electroporation. The beauty of DNA vaccines 
are they are easily designed, economical, and safe. The plasmid DNA can be engineered 
to express multiple antigens, linked epitopes, cytokines and adjuvants. In this report, the 
plasmid contains a Kozak sequence, an IgE leader sequence, and the codon-optimized 
WT1 consensus sequence. It excludes the zinc finger region, which can sequester the 
protein in the nucleus. These modifications along with in vivo electroporation, which 
increases the number of number of transfected cells and the number of plasmids per cell, 
greatly enhance protein expression of the antigen75,76. Additionally, the WT1 consensus 
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sequence is based on the alignment of WT1 homologs, which is used to create a more 
xenogeneic antigen that is 91% identical to the syngeneic antigen. Xenogeneic antigens 
are able to circumvent tolerance, because they are sufficiently different from the self-
antigen, but similar enough to produce compatible peptides46.  
These peptides may be heteroclitic in nature and/or affect proteasomal cleavage. 
Heteroclitic peptides have amino acid differences which can enhance TCR affinity to its 
pMHC and can increase the half-life of TCR-pMHC interaction. These changes may 
increase the binding of the peptide to MHC, thereby increasing the density of that 
peptide’s presentation on the surface of APCs, facilitating increased TCR engagement, T 
cell activation, and bolstering the immune response46,110. However, Speiser et al. would 
argue that functional avidity, gained by using the natural, unmodified peptide, is superior 
to the increased T cell frequencies gained by using the altered or heteroclitic peptide, 
when the vaccine formulation includes IFA and CpG111. If the peptides, identified in this 
study are not heteroclitic, the amino acids substitutions may still affect proteasomal 
cleavage. 
In the cytoplasm, the constitutive proteasome regularly degrades ubiquitinated 
proteins, preferring to cleave proteins after certain amino acids. After cells are induced by 
IFNγ exposure, the proteasome is reconfigured into the immunoproteasome, which has 
slightly different specificities for cleavage sites112,113. In either case, these peptides are 
translocated by the transporter associated with antigen processing (TAP), into the lumen 
of the endoplasmic reticulum (ER), where they are loaded onto MHC I for eventual 
presentation to CD8+ T cells114,115. Consensus peptide #28  which contains 
RMFPNAPYLPNCL, wherein the underlined “N” was a “S” in the murine WT1 
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sequence, has a better immunoproteasomal processing score with the substitution, 
according to T cell epitope prediction tools provided by the Immune Epitope Database 
and Analysis Resource (www.iedb.org)116. However, this does not take into account TAP 
transport and MHC binding, which then reveals that RMFPNAPYL is still the best 
epitope. In another example, murine peptide #19 contains LSAFTLHF, but the consensus 
sequence is LSAFTVHF, which again has a better immunoproteasomal processing score. 
Is it possible that better processing of the xenogeneic protein, more LSAFTVHF peptides 
produced and presented, activated LSAFTLHF-specific T cells? While T cell epitope 
prediction tools are useful, the epitope mapping assay needs to be repeated, and any 
proposed epitopes experimentally validated. Our current experiment identified two 15mer 
peptides with single amino acid substitutions that, upon further study, may reveal 
heteroclitic epitopes, or instead show how amino acids changes influence the peptides 












Figure 9.  Schematic of the consensus WT1 construct, and comparison of the consensus and the 
wild-type murine WT1 sequences.  
(A)  Schematic of WT1 protein to show major differences between the murine WT1 and consensus WT1 
sequences. The WT1 consensus sequence is based on the alignment of homologs of WT1 and further 
modified to include an IgE leader sequence and the removal of a proline rich region, the variably spliced 
exon 5, and zinc finger domains. (B) Amino acid alignment of the consensus sequence to the wild-type 









Figure 10.  Consensus WT1 DNA vaccine induces a stronger immune response than wild type 
murine WT1 DNA vaccine.  
Three WT1 DNA vaccines are compared: 1) the consensus WT1 construct pConWT1, 2) a construct in 
which an IgE leader is added to the murine WT1 sequence, pIgEL-WT1, and 3) the original wild type 
murine WT1 construct, pWT1. One week after the fourth vaccination (25 µg of DNA by IM injection 
followed by electroporation at injection site) splenocytes from C57BL/6 mice were stimulated in vitro 
with pooled consensus WT1 peptide for 24 hours in 96 well ELISpot plates coated with antibody to IFNγ. 
Individual mice are shown for each group. Each column represents the average of triplicates (+/-SD). 












Figure 11.  Increasing the amount of consensus WT1 DNA increases the immune response to wild 
type WT1 peptides. 
Increasing amounts of consensus WT1 DNA, pConWT1, were used to vaccinate mice (25 µg, 50 µg, and 
75 µg). One week after the fourth electrovaccination, splenocytes from C57BL/6 mice are stimulated in 
vitro with pooled wild type murine WT1 peptide for 24 hours in 96 well ELISpot plates coated with 
antibody to IFNγ, in triplicate. Data are representative of two independent experiments. Average (+/-SD) 




Figure 12.  Splenocytes from pConWT1-vaccinated mice do not respond to endogenously expressed 
WT1.  
Mice were vaccinated with 25 µg, or 75 µg of pConWT1. One week after the fourth vaccination, 
splenocytes from C57BL/6 mice were stimulated in vitro by B cells (untransfected B6BL#1153 B cells), a 
murine WT1 stably transfected B cell line (B1153-WT1) or WT1 mRNA transfected B6BL#1153 B cells 
(WT1 B cells) for 24 hours in 96 well ELISpot plates coated with antibody to IFNγ, in triplicate. Data are 





Figure 13.  Identification of a 15-mer peptide containing a dominant T cell epitope from the 
consensus WT1 library.  
(A) Spleen cells from mice vaccinated with 25 µg pConWT1, and from naive mice were screened by an 
IFN-γ ELISpot epitope mapping assay for responses to consensus WT1 library peptides. Data are from a 
pilot experiment and have not been repeated. Average (+/-SD) of five mice per group. (B) Composition 
of the consensus WT1 library peptide pools 1 to 17 used for combinatorial screening of specific T cell 
responses. Individual library peptides identified by screening were darkly shaded. In italics was the 





Figure 14.  Identification of two 15-mer peptides containing T cell epitopes from the wild type 
murine WT1 library.  
(A) Spleen cells from mice vaccinated with 25 µg pConWT1, and from naive mice were screened by an 
IFN-γ ELISpot epitope mapping assay for responses to wild type murine WT1 library peptides. Data are 
from a pilot experiment and have not been repeated. Average (+/-SD) of five mice per group.  (B) 
Composition of the wild type WT1 library peptide pools 1 to 18 used for combinatorial screening of 
specific T cell responses. Individual library peptides determined by screening were darkly shaded. In 








Figure 15.  Alignments of the peptides identified from each of the peptide libraries.  
Outlined in black and aligned to both the wild type murine WT1 and the consensus WT1 sequences was 
the identified 15-mers from the (A) consensus WT1 peptide library, and the (B) wild type murine WT1 
peptide library. Grey and black sections along the conservation bar indicated regions of mismatch 




Chapter 4: Conclusions and Future directions 
WT1, a transcription factor, essential for embryonic development, is highly 
homologous across species, and is unmutated and overexpressed in wide variety of 
cancers30. To create a vaccine that can potentially initiate tumor rejection to this self-
antigen, a “mutated” or xenogeneic version of the antigen was designed. A reduction of 
9% similarity to murine WT1 was able to induce a substantial CTL immune response in 
mice. In comparison to human WT1, the consensus WT1 sequence is 6% different, which 
could induce immune responses, but may be insufficient to circumvent tolerance. 
However, since this a DNA vaccine, further modifications, such as addition of a DC-
LAMP sequence to enable presentation by class I and class II MHCs, can easily be 
engineered to make it more immunogenic, and potentially a potent tumor immunotherapy 
accessible to wide range of patients117.  
Future studies utilizing pConWT1 will feature tumor therapy and tumor challenge 
experiments, to determine whether pConWT1 can activate immune cells that recognize 
and kill tumor cells that endogenously express WT1. Previous reports, as well as our 
results showed that splenocytes from WT1-vaccinated mice responded to WT1 peptide 
but not to WT1-expressing cells. This may indicate that naturally processed WT1 
peptide/MHC density, on the surface of the stimulator cell, is insufficient and is below 
the threshold necessary for cells predisposed towards tolerance103,118. Ramirez et al. 
experienced suboptimal results in that their peptide-loaded DCs were able to produce 
WT1-specific CTLs, but such CTLs were unable to recognize endogenously expressed 
WT1 from cell lines such as TRAMP-C2 or WT1 transfected RMA-S cells103. This may 
signify that for a potent and functional vaccine and rejection of tumor, pConWT1 may 
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have to be combined with genetic adjuvants such as IL-12, a proinflammatory cytokine, 
or be administered concurrently with PD-1 (or PD-L1) blockade to break peripheral 
tolerance.  
Another interpretation of the negative result with WT1-expressing B cells is that 
the peptides antigens which primed the splenocytes from the pConWT1-vaccinated mice 
were likely from an immunoproteasome, while the peptides displayed on these WT1-
expressing B cells may be from a constitutive proteasome119,120. Further characterization 
of the B6BL#1153 B cell line would be useful. Determining which proteasomal subunits 
are expressed may help explain our results. If it were true that splenocytes from 
pConWT1-vaccinated mice preferentially respond to peptides from the 
immunoproteasome, it would affect tumor challenge and therapy experiments, as 
manipulation of the WT1-expressing tumor microenvironment would need to occur. IFNγ 
is known to increase tumor immunogenicity121,122. Mejias et al have reported that, by 
using IFNγ adsorbed magnetic particles, and an external magnetic field, they were able to 
target and deliver the cytokine directly to the tumor and minimize systemic toxicity123. 
Among the multiple responses mediated by IFNγ, treatment with IFNγ enhanced tumor 
immunogenicity possibly by converting the constitutive proteasome to an 
immunoproteasome to create a different set of peptides.  
A more direct method of identifying what peptides are displayed on the surface of 
the cell, as demonstrated by Riemer et al., uses a “predict/detect” technique124. This 
requires a set of peptides, defined by predictive programs, such as those available at 
Immune Epitope Database and Analysis Resource, and peptides eluted from cell lines of 
interest. By using an “MS3 Poisson detection mass spectrometry approach…[one can] 
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directly assess the physical presence of predicted CTL target epitopes on tumors” and 
quantify the number of copies of the epitope displayed on the cell124. Success with this 
method may hinge on the accuracy of the predicted peptides; however, to know precisely 
what peptide is being presented by an MHC in a particular cell is a powerful tool for 
vaccine development. Even though our consensus WT1 vaccine utilizes as much of the 
antigen as possible, not just predicted epitopes, such a tool could help elucidate the 
presentation of the consensus antigen on APCs, in comparison to the presentation of wild 
type antigen on tumor cells. 
In this report, the consensus WT1 DNA vaccine substantially increased CTL 
immune responses as compared to the wild type murine WT1 DNA vaccine. Murine 
peptides, EEQCLSAFTLHFSGQ and PSQASSGQARMFPNA, have been identified that 
stimulate cells ex vivo from consensus WT1-vaccinated mice. Ideally, once low avidity T 
cells are activated by xenogeneic antigen, and differentiated into memory T cells, they 
may be restimulated by the same wild type antigen that could not activate their naïve 
counterparts, and therefore be better able to identify and to kill tumor expressing wild 
type WT1. While the RMFPNAPYL epitope was unchanged within the consensus 
sequence, a neighboring amino acid was changed from serine to asparagine, which has 
the potential to affect proteasomal processing of the protein. A potential experiment 
would involve making that one amino acid substitution in the WT1 mRNA used to 
transfect the B6BL#1153 B cell line, to determine whether that change could truly affect 
presentation of WT1 to splenocytes from consensus WT1-vaccinated mice. Further study 
will need to be done to confirm and define the minimal epitopes contained within these 
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